Myelodysplasia following aplastic anaemia–paroxysmal nocturnal haemoglobinuria syndrome after treatment with immunosuppression and G‐CSF: evidence for the emergence of a separate clone

1996/09/01 by Jong‐Youl Jin, J. Adam Tooze, Jennifer A. Tooze +4
Immunology and Microbiology · Medicine · #Complement system in diseases #Neutrophil, Myeloperoxidase and Oxidative Mechanisms #Platelet Disorders and Treatments

paper · doi:10.1046/j.1365-2141.1996.d01-1831.x

Abstract

Myelodysplasia (MDS) and aplastic anaemia-paroxysmal nocturnal haemoglobinuria (AA/PNH) syndrome developed in a severe aplastic anaemia (AA) patient after treatment with immunosuppressive (IS) therapy. Glycosylphosphatidyl inositol (GPI)-linked proteins were determined, and during the AA/PNH phase, a high proportion of neutrophils were found to be negative, without clinical evidence of haemolysis. However, MDS developed with cytogenetic abnormalities of monosomy 7,9q- and a rearranged chromosome 6; the GPI-linked protein negative cells were completely replaced by positively expressing cells. This represents the emergence of a GPI-linked protein positive myelodysplasia clone arising separately from an AA/PNH clone.

Related

• Long‐term administration of G‐CSF for aplastic anaemia is closely related to the early evolution of monosomy 7 MDS in adults
• Aplastic anemia: Etiology, molecular pathogenesis, and emerging concepts
• The incidence and prevalence of patients with paroxysmal nocturnal haemoglobinuria and aplastic anaemia PNH syndrome: A retrospective analysis of the UK’s population‐based haematological malignancy research network 2004‐2018
• Diagnosis of Myelodysplastic Syndrome Among a Cohort of 119 Patients With Fanconi Anemia
• Acquired severe aplastic anemia